BridgeBio's 'baffling' heart disease drug fail 'de-intensifies' competition for Alnylam

BridgeBio's shot at entering a competitive market for a rare heart condition narrowed Monday after a "baffling" result in a phase 3 clinical trial where placebo patients bested those who received the treatment in a walk test. 

Related Keywords

Alnylam Onpattro ,Jeff Preis ,Neil Kumar ,Pfizer , ,Bridgebio Pharma ,Alnylam Pharmaceuticals ,Failed Trials ,Clinical Trial Results ,Cardiomyopathy ,Amyloidosis ,Heart Drug ,Heart Failure ,